POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN THE PRACTICE OF A PEDIATRIC NEUROLOGIST
Keywords:
PRES, acute lymphoblastic leukemia, childrenAbstract
Posterior reversible encephalopathy syndrome (PRES) is considered a clinical-radiological syndrome characterized by headaches, seizures, altered consciousness, and visual disturbances. This syndrome was first described in 1996 by Hinchey et al. With the widespread use of brain MRI, the diagnosis of this syndrome has become possible. Objective of the clinical observation to describe PRES in a patient with acute lymphoblastic leukemia who received pre-treatment with dexamethasone. We present a case of a child with posterior reversible encephalopathy syndrome in the context of acute lymphoblastic leukemia during the induction phase of remission. The child received timely symptomatic therapy in the intensive care unit. Brain MRI was performed, which helped establish the diagnosis for the patient in a timely manner.
References
Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. NEnglJMed. 1996;334:494–500.
Kim SJ, Im SA, Lee JW, et al. Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia. Pediatr Neurol. 2012;47:436–442.
Baytan B, Evim MS, Guler S, Gunes AM, Okan M. Acute central nervous system complications in pediatric acute lymphoblastic leukemia. Pediatr Neurol. 2015;53:312–318.
Banerjee JS, Heyman M, Palomaki M, et al. Posterior reversible encephalopathy syndrome: risk factors and impact on the outcome in children with acute lymphoblastic leukemia treated with Nordic protocols. J Pediatr Hematol Oncol. 2018;40:e13–e18.
Parasole R, Petruzziello F, Menna G, et al. Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leuk Lymphoma. 2010;51:1063–1071.
Khan RB, Sadighi ZS, Zabrowski J, Gajjar A, Jeha S. Imaging patterns and outcome of posterior reversible encephalopathy syndrome during childhood cancer treatment. Pediatr Blood Cancer. 2016;63:523526.
Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914–925.
Narbone MC, Musolino R, Granata F, Mazzu I, Abbate M, Ferlazzo E. PRES: posterior or potentially reversible encephalopathy syndrome? Neurol Sci. 2006;27:187–189.
Irvin W, MacDonald G, Smith JK, Kim WY. Dexamethasoneinduced posterior reversible encephalopathy syndrome. J Clin Oncol. 2007;25:2484–2486.
Nguyen MT, Virk IY, Chew L, Villano JL. Extended use dexamethasoneassociated posterior reversible encephalopathy syndrome with cisplatin-based chemotherapy. J Clin Neurosci. 2009;16:1688–1690.
Hourani R, Abboud M, Hourani M, Khalifeh H, Muwakkit S. Lasparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008;39:46–50.
Ryan SA, Maceneaney P, O'Reilly SP, Moylan EJ, Power DG. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol. 2012;29:1287–1291.
Aulakh P, Fatakhov E, Koch CF, Jr, Kapil S. Posterior reversible encephalopathy syndrome with documented hyponatraemia. BMJ Case Rep. 2013;2013.
